IL1B and myocardial infarction: Great interest has been aroused by the effect of a therapeutic monoclonal antibody targeting IL-1β, canakinumab, whose administration led, in a large cohort of patients with previous myocardial infarction, to a significantly lower rate of recurrent cardiovascular events [67].